Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ALK-1/ACVRL1 Protein, 100µg  

Recombinant human ALK-1/ACVRL1 Protein, 100µg

Recombinant human ALK-1 /ACVRL1 Protein (rhALK1), Asp22-Gln118 was expressed in human 293 cells (HEK293)

Synonym
recombinant, human, protein ACVRL1, ACVRL-1, ACVRLK1, ALK-1, ALK1, HHT, HHT2, HHT-2, ORW2, ORW-2, SKR3, SKR-3, TSR-I

More details

AL1-H5227-100

Availability: within 7 days

312,00 €

Background
Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene[1-2]. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic [3]. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells[4].

Source
Recombinant human ALK-1 /ACVRL1 Protein (rhALK1), Asp22-Gln118 (Accession # NP_000011.2) was expressed in human 293 cells (HEK293)

Molecular Characterization
rhALK1, a 108 amino acids protein with polyhistidine tag at C-terminus, and has a calculated MW of 12.3 kDa. The predicted N-terminus is Asp22. DTT-reduced protein migrates as 26 kDa protein due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhALK1 by the LAL method.

Purity
>97% purity as determined by SDS-PAGE of reduced rhALK1.

Formulation
Refer to data sheet

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A

References

(1) Ten Dijke P, Ichijo H, et al. (Oct 1993). Oncogene 8 (10): 2879–87
(2) Johnson DW, Berg JN, et al.(Jul 1996). Nat Genet 13 (2): 189–95
(3) Lawlor MW, Read BP, et al. (Feb.2011). Am J Pathol. 178(2):784-93
(4) Mitchell D,et al.(Feb. 2010). Mol Cancer Ther.. 9(2):379-88